UTILISATION DES PROTÉINES PD-1 ET CD38 COMME MARQUEURS D'UNE PATHOLOGIE AUTO-IMMUNE ACTIVE

European patent · EP4212877 · In force

Register entry

Publication number
EP4212877
Application number
EP23156126
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
May 19, 2020
Published
Jul 19, 2023
Granted
Mar 19, 2025
Protection ends at the latest
May 18, 2040
Next annual fee due
May 31, 2026
IPC classes
G01N 33/564 (2006.01)
Priority
FR 1905358 22.05.2019
Divided from
EP20726132
Filing language
French
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jan 28, 2026

    Change

    Published in Swissreg on 28.01.2026

  2. Jun 11, 2025

    Agent entered

    Representative
    Novagraaf International SA, Chemin de l'Echo 3, 1213 Onex

    Published in Swissreg on 11.06.2025

  3. Jun 1, 2025

    Change

    Published in Swissreg on 01.06.2025

  4. Mar 19, 2025

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 19.03.2025

Parties

Inventor

RENAND, Amédée

44980 SAINTE-LUCE-SUR-LOIRE, FR

CONCHON, Sophie

44300 NANTES, FR

GOURNAY, Jérôme

44100 NANTES, FR

AUBLE, Hélène

44000 NANTES, FR

HABES, Sarah

44200 NANTES, FR

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.